FdaApplication
NDA 214998
Identifiers
- fda_app_no: NDA214998
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2022-04-28 |
Revenue by product
CAMZYOS
| Period | Revenue |
|---|---|
| Q2 2026 | $416.0M |
| Q1 2026 | $314.0M |
| Q4 2025 | $354.0M |
| Q3 2025 | $296.0M |
| Q2 2025 | $260.0M |
| Q1 2025 | $159.0M |
| Q4 2024 | $223.0M |
| Q3 2024 | $156.0M |
| Q2 2024 | $139.0M |
| Q1 2024 | $84.0M |
| Q4 2023 | $88.0M |
| Q3 2023 | $68.0M |
| Q2 2023 | $46.0M |
| Q1 2023 | $29.0M |
| Q4 2022 | $16.0M |
| Q3 2022 | $5.0M |
| Q2 2022 | $3.0M |
| Q1 2022 | $0.0M |
| Q4 2021 | $0.0M |
| Q3 2021 | $0.0M |
| Q2 2021 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CAMZYOS | MAVACAMTEN | 10MG | CAPSULE;ORAL |
| CAMZYOS | MAVACAMTEN | 5MG | CAPSULE;ORAL |
| CAMZYOS | MAVACAMTEN | 15MG | CAPSULE;ORAL |
| CAMZYOS | MAVACAMTEN | 2.5MG | CAPSULE;ORAL |
4 products